ND047

ND047 is a multispecific antibody and T-cell engager currently in the research stage of development by Numab Therapeutics. It is being investigated for the treatment of gastrointestinal cancers and other oncological indications. The molecule is engineered using Numab's proprietary MATCH (Multispecific Antibody-based Therapy by Cognate Heterodimerization) platform, which allows for the flexible assembly of antibody fragments into stable, multispecific biologics. As a T-cell engager, ND047 is designed to simultaneously bind to a tumor-associated antigen and the T-cell receptor complex to facilitate the recruitment and activation of cytotoxic T-cells against cancer cells. While the specific molecular targets for ND047 have not been publicly disclosed, the program is part of Numab's broader strategy to develop next-generation immunotherapies for solid tumors.